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Laboratory observations regarding interactions of innate immunity and the vascular endothelium have established that inflammation plays a role in all stages of the atherothrombotic process, from early foam cell formation to late plaque rupture. 1 Epidemiological evidence supporting the inflammatory hypothesis of atherosclerosis initially derived from studies of those with acute ischaemia 2 or from otherwise healthy patient populations 3 in which biomarkers of inflammation such as C-reactive protein were observed to predict short-and long-term vascular risk. An equally intriguing set of clinical data linking inflammation to atherosclerosis has come from studies of patients with rheumatoid arthritis, inflammatory bowel disease, and periodontal disorders. 4, 5 In these studies, patients with systemic chronic inflammatory conditions have consistently been found at elevated vascular risk compared with agematched controls, even after adjustment for traditional risk factors. Taken together, these laboratory and clinical data have led to a new understanding of atherosclerotic pathophysiology that has implications for both prevention and treatment. In 2006, the paradigm that individuals affected by inflammation have elevated vascular risk was extended by Gelfand and colleagues to include psoriasis, a common prototypical helper T cell type 1 (Th1) inflammatory disorder that leads to scaly erythematous plaques in the skin and in some patients to psoriatic arthritis. 6 Using prospective data from the UK General Practice Research Database collected between 1987 and 2002, Gelfand and colleagues initially reported that the incidence of myocardial infarction per 1000 person-years for unaffected controls, those with mild psoriasis, and those with severe psoriasis was 3.58, 4.04, and 5.13, respectively. These investigators also reported that the relative risks of future myocardial infarction associated with psoriasis varied by age and severity, with the greatest risk observed among those with severe disease and young age. Conversely, the lowest risk was observed among those with mild psoriasis and older age. This modification of cardiovascular risk by both age and disease severity is important as psoriasis is a heterogeneous disorder such that those with more severe disease at younger ages tend also to have more severe innate immune dysfunction. Thus, a dose-response relationship between the extent of inflammation and subsequent vascular risk was demonstrated in this prospective cohort. Implicating a systemic pro-atherosclerotic process, Gelfand and colleagues have also separately demonstrated in this cohort that psoriasis patients are at increased risk of stroke.
Mehta et al. have used the same UK General Practice Research Database to extend these observations to cardiovascular mortality. 7 In their analysis, 3603 patients with severe psoriasis and 14 330 unexposed patients were identified and followed prospectively for cardiovascular mortality. Consistent with the hypothesis that Th1 inflammation is central to insulin resistance and premature atherosclerosis, those with severe psoriasis had a higher prevalence of hypertension, hyperlipidaemia, and diabetes. As would be anticipated in a study of severe psoriasis, almost 60% of the cases were taking methotrexate and 25% were taking azathioprine or cyclosporine.
Over an average follow-up of 3.4 years, 3.0% of the severe psoriasis group died from cardiovascular causes as compared with 2.1% of the control group, a relative hazard ratio of 1.57 [95% confidence interval (CI) 1.26-1.96) after adjustment for age, gender, smoking, diabetes, hypertension, and diabetes. As in the original paper describing myocardial infarction, relative risks in the analysis of Mehta et al. for cardiovascular death were higher at younger age, suggesting that early-onset psoriasis confers greater vascular risk than disease with late onset.
In neither study were measures of C-reactive protein available, so it is not possible within the current data to address whether the effects of psoriasis are independent of anticipated elevations of C-reactive protein. Nonetheless, these findings are of interest as the magnitude of risk associated with severe psoriasis in both analyses was not only similar to the magnitude of risk associated with LDL-cholesterol (LDL-C), smoking, and hypertension in the same patient cohort, but it was also virtually identical to risk estimates seen in prior studies of patients with rheumatoid arthritis as well as the magnitude of risk found in recent meta-analyses for Creactive protein. 8 As such, the current data demonstrate that the inflammation of psoriasis is far more than skin deep-for affected patients, the systemic nature of the Th1 inflammatory defect impacts not only the skin and joints, but on the endothelium as well.
What clinical messages can be taken from these observations? As a routine part of general medical care, otherwise healthy individuals with moderate to severe psoriasis should be recognized
Less certain is whether or not individuals with severe psoriasis and low levels of LDL-C should be considered candidates for statin therapy. Many patients with severe psoriasis have elevated Creactive protein levels and, in the recent Justification for the Use of statin in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study, 9 rosuvastatin 20 mg daily reduced rates of first ever myocardial infarction, stroke, and cardiovascular death in a population who would not qualify for statin therapy due to low LDL-C levels (,3.4 mmol/L), but who were at increased vascular risk due to elevations of C-reactive protein (.2 mg/L). Specifically, within the JUPITER trial, statin use among those with low LDL-C and elevated C-reactive protein resulted in a 44% reduction in the primary trial endpoint (P ,0.0001), a 54% reduction in myocardial infarction (P ¼ 0.0002), a 48% reduction in stroke (P ¼ 0.002), a 46% reduction in need for bypass surgery or angioplasty (P ,0.0001), a 43% reduction in venous thrombo-embolism (P ¼ 0.007), and a 20% reduction in all cause mortality (P ¼ 0.02). 9 At face value, the JUPITER study provides clinical data corroborating observations that in addition to potently inhibiting cholesterol synthesis, statins reduce inflammatory cell adhesion and monocyte recruitment to endothelial cells, alter smooth muscle migration in developing plaques, favourably affect matrix metalloproteinases, and in human hepatocytes reduce interleukin-6 (IL-6)-induced Creactive protein production. 10 All of these effects suggest antiinflammatory effects of statin therapy, a hypothesis further supported by findings both in acute coronary ischaemia and in primary prevention that the best clinical outcomes following initiation of statin therapy occur among those who achieve the 'dual goals' of both aggressive LDL-C and C-reactive protein reduction. 11, 12 On the other hand, individuals with chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, and severe psoriasis were excluded from the JUPITER trial, so extrapolation of these data must be done with caution. What remains unknown is whether targeted anti-inflammatory therapies might have a role in preventing atherosclerotic vascular events. Currently available inhibitors of both tumour necrosis factor-a (TNF-a) and IL-6 appear to increase lipid levels and may carry other systemic toxicities, making trials of these agents among vascular patients difficult to initiate. One pilot study of IL-1b inhibition is ongoing among individuals with acute coronary ischaemia, 13 and similar agents are being developed with promising applications for both diabetes and vascular disease.
As recently proposed, very low-dose methotrexate (VLDM, 10 -15 mg weekly) might also be an effective agent to test the inflammatory hypothesis of atherothrombosis directly.
14 VLDM is a well-tolerated drug of choice for most patients with rheumatoid arthritis and has a known toxicity profile that can be managed according to guidelines from the American College of Rheumatology. As proposed in the Cardiovascular Inflammation Reduction Trial (CIRT) protocol, 14 VLDM could be compared with placebo among post-myocardial infarction patients and those with stable atherosclerotic disease who are already on a background of aspirin, statins, b-blockers, and inhibitors of the angiotensinconverting enzyme system, but who remain at risk due to persistently elevated levels of C-reactive protein ( Figure 1 ). Given the safety profile and proven anti-inflammatory efficacy of VLDM established in the arthritis community, this approach could provide direct evidence as to whether or not inhibition of inflammation reduces vascular event rates using an agent that does not have concomitant beneficial effects on lipids (such as a statin) or platelet function (such as aspirin).
In support of the CIRT trial concept, non-randomized observational studies report reductions in vascular events and cardiovascular death among both rheumatoid arthritis and psoriasis patients being treated with weekly methotrexate in doses ranging from 10 to 20 mg 15 ( Table 1) . Given these observational data, it is of interest that more than half of the severe psoriasis patients followed for vascular mortality were taking methotrexate; at least from an epidemiological perspective, the hazard ratios observed in the UK General Practice Research Database might, if anything, underestimate the true risk associated with severe psoriasis. Additional studies in independent cohorts are needed to address the consistency of these observations. In the meantime, Editorial it may be prudent to provide all psoriasis patients with information on the proven vascular benefits that accompany weight loss, dietary discretion, smoking cessation, and increased daily exercise. Editorial
